--- title: "Enhabit Faces Shareholder Suits Over Kinderhook Take-Private Deal" type: "News" locale: "en" url: "https://longbridge.com/en/news/285214299.md" description: "Enhabit, Inc. is facing multiple shareholder lawsuits regarding its acquisition by Kinderhook Industries, which aims to take the company private. The lawsuits challenge the adequacy of proxy disclosures and valuation work by Goldman Sachs. In response, Enhabit has supplemented its proxy with additional details about the sale process and board deliberations. The stockholder vote is scheduled for May 12, 2026. Analysts currently rate EHAB stock as a Hold with a price target of $13.80, reflecting a neutral outlook due to improving financial performance but ongoing net losses." datetime: "2026-05-05T13:06:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285214299.md) - [en](https://longbridge.com/en/news/285214299.md) - [zh-HK](https://longbridge.com/zh-HK/news/285214299.md) generator: "portal-rs" --- # Enhabit Faces Shareholder Suits Over Kinderhook Take-Private Deal ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Enhabit, Inc ( (EHAB) ) is now available. Enhabit, Inc., a home health and hospice provider, agreed on February 22, 2026 to be acquired by Anchor Parent, LLC, an affiliate of Kinderhook Industries, through a merger that will take Enhabit private, following an extended multi-party strategic review that included several potential financial and strategic bidders. The company has since faced multiple stockholder lawsuits and demand letters in New York and California challenging the adequacy of its proxy disclosures around the merger process, valuation work by Goldman Sachs, and potential conflicts of interest; to avoid delays and costs and without admitting wrongdoing, Enhabit has supplemented its proxy with extensive additional detail on the sale process, confidentiality and standstill arrangements, board deliberations, litigation considerations, and the financial analyses underlying the deal, ahead of a May 12, 2026 stockholder vote. Enhabit’s supplemental disclosures describe how numerous parties entered confidentiality agreements with standstill provisions, the board weighed alternatives including remaining independent or asset divestitures, and Kinderhook’s offer ultimately prevailed after negotiations over termination fees, go-shop terms and the removal of a contingent value right in favor of higher upfront value. The filing also elaborates on Goldman Sachs’ discounted cash flow, trading and transaction analyses, its limited concurrent mandate for Kinderhook on an unrelated matter, and Enhabit’s assessment that no reliable value could be assigned to ongoing Delaware and Texas litigations, information that responds directly to shareholder allegations while seeking to preserve the transaction timeline and certainty for investors. The most recent analyst rating on (EHAB) stock is a Hold with a $13.80 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page. **Spark’s Take on EHAB Stock** According to Spark, TipRanks’ AI Analyst, EHAB is a Neutral. The score is driven primarily by improving financial performance supported by strong cash generation, alongside constructive (but not strong) technicals. These positives are partially offset by weak valuation signals due to ongoing net losses, while corporate events are favorable given the progressing take-private transaction and related financing/legal updates. To see Spark’s full report on EHAB stock, click here. **More about Enhabit, Inc** Enhabit, Inc. is a U.S.-based provider of home health and hospice services, operating as a public company focused on post-acute care. The company’s business depends heavily on Medicare reimbursement dynamics and strategic transactions that can influence its capital structure and ownership, drawing interest from private equity sponsors and strategic acquirers in the healthcare sector. **Average Trading Volume:** 1,563,721 **Technical Sentiment Signal:** Buy **Current Market Cap:** $703.8M Learn more about EHAB stock on TipRanks’ Stock Analysis page. ### Related Stocks - [EHAB.US](https://longbridge.com/en/quote/EHAB.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [Enhabit (NYSE:EHAB) CAO Sells $19,094.83 in Stock](https://longbridge.com/en/news/278810559.md) - [Jana Partners Buys Stake in Data Center Stock Everpure, May Be Up Almost 100% Already](https://longbridge.com/en/news/296256974.md) - [Tudor Investment Corp ET AL Sells 74,355 Shares of Enhabit, Inc. $EHAB](https://longbridge.com/en/news/282511277.md) - [Enhabit (NYSE:EHAB) EVP Sells $38,068.59 in Stock](https://longbridge.com/en/news/278810581.md) - [Uncovering Potential: Enhabit's Earnings Preview](https://longbridge.com/en/news/277643345.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**